Mike joined King's College London and founded the King's Commercialisation Institute (KCI) in 2012. The aims of KCI include providing entrepreneurial awareness and support for the commercial translation of life science research so it can be embraced by industry and private investors for impact delivery. KCI conducts an annual peer review and triage for commercial appeal of the King's College London and King's Health Partners (KHP) life science research portfolio and selects projects for support by the King's Health Accelerator which KCI manages. The accelerator provides project funding and specialist industrial support for its portfolio of technologies with an aim of commercially translating great science to transformative product solutions that benefit patients and society.
Prior to joining King's College London, Mike led an industrial consultancy practice based in the NHS innovation hub serving the Midlands and East of England and prior to that, the pharmaceutical industry where his thirty one (31) year career spanned the globe. His experience includes twelve (12) years in pharmaceutical sales and marketing in the USA with Wellcome followed by nineteen (19) years based in the UK but having global management responsibilities. Mike led the commercial development of three blockbuster (sales >$1bn per annum) antiviral products (Retrovir (zidovudine), Valtrex (valaciclovir) & Viread (tenofovir df)) at Wellcome, GlaxoWellcome and Gilead Sciences. He was subsequently CEO of Molecular Skincare Ltd which he later sold to York Pharma Plc and joined its Board as Commercial Director where £50mil in investment finance was raised and three corporate acquisitions were achieved.